Cancer of the liver
Conditions
Interventions
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) liver cancer patients with pathological or clinical diagnosis; 2) patients who have received or are receiving conventional treatments such as surgery, interventional therapy and targeted therapy; 3) 18-75 years old, regardless of gender; 4) the subjects voluntarily agree to participate in the observation, and can closely cooperate in the treatment observation; 5) subject or authorized agent agrees and signs the informed consent.
Exclusion criteria
Exclusion criteria: 1) patients whose survival is expected to be less than 6 months; 2) patients undergoing systemic chemotherapy and immunotherapy; 3) patients with high fever and severe local or systemic infections (including respiratory tract, genitourinary system, digestive system, sepsis, etc.); 4) language barrier, unable to express their own will; 5) patients who are difficult to accurately evaluate the safety and efficacy of the product; 6) patients with uncontrolled hypertension, heart and lung failure, patients with thrombophlebitis, severe bleeding tendency and risk of massive bleeding (there is a history of bleeding in esophageal varices); 7) patients with severe heart, brain, liver, kidney, hematopoietic, endocrine system problems, or mental illness; 8) participants in other clinical trials within 2 weeks before enrollment; Patients who had received immunotherapy within the first 4 weeks of enrollment; 9) suspected or true history of alcohol or drug abuse; 10) active patients with hepatitis a, hepatitis b, AIDS, tuberculosis and other infectious diseases and connective tissue diseases; 11) pregnant women; 12) patients considered by the investigator to be unsuitable to participate in this clinical trial. (use a checklist to list conditions that affect the efficacy or safety assessment of the study, such as other treatments contrary to the inclusion criteria, co-existing diseases, and pregnancy.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A total of 75 immune cell markers were detected and differential indicators were selected.; | — |
Countries
China
Contacts
Public ContactDuanming Du
Shenzhen Second People's Hospital
Outcome results
None listed